Patient Experience and Acceptance of Horizontal Rotation
Launched by UNIVERSITY OF SYDNEY · Dec 13, 2016
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how patients with cancer feel about a new system that rotates them horizontally at different speeds. The goal is to understand their experiences and acceptance of this rotation, which could help improve treatments in the future. Participants will fill out surveys designed to measure their feelings and experiences during the rotation process.
To be eligible for this trial, you need to be at least 18 years old and have a cancer diagnosis at any stage. You should also be currently or previously treated with radiotherapy. It’s important that you can read and complete questionnaires in English and are willing to follow the study's requirements. However, pregnant women and those with certain medical conditions that might affect their ability to give consent or experience severe dizziness are not eligible. If you choose to participate, you will play a vital role in helping researchers better understand how this rotation affects patients like you.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. A diagnosis of cancer, any stage
- • 2. ≥18 years of age
- • 3. Eastern Cooperative Oncology Group (ECOG) status 0-2
- • 4. Currently or previously being treated with radiotherapy
- • 5. Any prior therapy allowed
- • 6. Willing and able to comply with all study requirements
- • 7. Must be able to read and complete questionnaires in English
- • 8. Signed, written informed consent
- Exclusion Criteria:
- • 1. Pregnant women
- • 2. Mentally impaired patients or patients for whom attaining informed consent would be difficult (including language barriers)
- • 3. Severe vertigo or recent diagnosis of Benign Paroxysmal Positioning Vertigo
About University Of Sydney
The University of Sydney is a leading research institution in Australia, renowned for its commitment to advancing medical science and improving healthcare outcomes through innovative clinical trials. With a robust infrastructure and a multidisciplinary team of experts, the university fosters a collaborative environment that integrates cutting-edge research with clinical practice. The institution emphasizes ethical standards, patient safety, and scientific rigor in its trials, aiming to translate findings into real-world applications that benefit diverse populations. Through its dedication to excellence and impact, the University of Sydney continues to contribute significantly to the fields of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Randwick, New South Wales, Australia
Patients applied
Trial Officials
Paul Keall, Prof
Study Chair
University of Sydney
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials